Testosterone Replacement Therapy Market is Predominantly Driven by the Increasing Geriatric Population; Asserts SMI Releasing the Industry Forecast for 2019–2025 | Eli Lilly and Company, Pfizer, Inc., Actavis (Allergan), Bayer Corporation, Novartis, Tev

In this report, the global Testosterone Replacement Therapy market is valued at USD XX million in 2019 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2019 and 2025.

Global Testosterone Replacement Therapy – Insights

Testosterone replacement therapy (TRT) is used for the treatment of symptomatic hypogonadism in men. TRT may offer benefits such as increased libido and energy level. It also offers a cardioprotective effect and increasing muscle strength. Such positive results have led to increasing use of testosterone replacement for men with symptomatic hypogonadism, which is expected to boost growth of the global testosterone replacement therapy market over the forecast period.

High prevalence of hypogonadism is expected to boost growth of the global testosterone replacement therapy market. Although hypogonadism is often under-reported, some studies suggest that 40% of men over the age of 45 and 50% of men in their 80s are hypogonadal. Moreover, increasing incidence of diabetes is also expected to propel growth of the market. For instance, according to the study, ‘Hypogonadotropic Hypogonadism in Men With Diabesity’, published in the journal ADA Diabetes Care in July 2018, hypogonadotropic hypogonadism is found in 25–33% of men with diabesity.

Download Free Sample Copy of Testosterone Replacement Therapy Market Report from Industry Experts @ https://www.stratagemmarketinsights.com/sample/8711

Increasing geriatric population is expected to offer lucrative growth opportunities for players in the global testosterone replacement therapy market. For instance, according to the World Health Organization, geriatric population is expected to reach 2 billion by 2050, up from 900 million in 2015.

However, TRT has been linked to some adverse effects such as prostate cancer, benign prostatic hyperplasia, polycythemia, and obstructive sleep apnea, which is expected to hinder growth of the global testosterone replacement therapy market. Moreover, various bans on the use of testosterones by various governments across the globe is also expected to hamper the market growth. For instance, in the U.S., the Nevada State Athletic Commission banned TRT from combat sports in 2014.

Key players in the market are focused on adopting product approval and launch strategies to expand their product portfolio. For instance, in March 2019, Clarus Therapeutics, Inc. received approval for JATENZO — testosterone undecanoate capsules for oral use from the U.S. FDA for TRT in adult males.

Key players in the market are also focused on adopting partnership and collaboration strategies to expand their product portfolio. For instance, in December 2019, Acerus Pharmaceuticals Corporation announced that the revised commercial partnership agreement with Aytu Bioscience to accelerate the growth of NATESTO – a nasal gel formulation of testosterone developed by Acerus Pharmaceutical Corporation – in the U.S. is now closed and fully effective as of December 1, 2019.

Key Takeaways:

• Increasing use of testosterone replacement for men with symptomatic hypogonadism is expected to augment growth of the global testosterone replacement therapy market

• Adverse effects of TRT such as prostate cancer, benign prostatic hyperplasia, polycythemia, and obstructive sleep apnea are expected to hamper the market growth

• Major players operating in the global testosterone replacement therapy market include, Clarus Therapeutics, Inc., Acerus Pharmaceutical Corporation, AbbVie, Endo International, Eli Lilly and Company, Pfizer, Inc., Actavis (Allergan), Bayer Corporation, Novartis, Teva Pharmaceuticals, Mylan, Upsher-Smith, Ferring Pharmaceuticals, and Kyowa Kirin

Get More Information on Testosterone Replacement Therapy Sales Market Research Report - Global Forecast till 2026 @ https://www.stratagemmarketinsights.com/quiry/8711

Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Testosterone Replacement Therapy for these regions, from 2019 to 2025 (forecast), covering
* United States
* China
* Europe
* Japan
* Southeast Asia
* India

Global Testosterone Replacement Therapy market competition by top manufacturers/players, with Testosterone Replacement Therapy sales volume, Price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
* AbbVie
* Endo International
* Eli lilly
* Pfizer
* Actavis (Allergan)
* Bayer
* Novartis
* Teva
* Mylan
* Upsher-Smith
* Ferring Pharmaceuticals
* Kyowa Kirin
* Acerus Pharmaceuticals

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
* Gels
* Injections
* Patches
* Other

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Testosterone Replacement Therapy for each application, including
* Hospitals
* Clinics
* Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Get Impressive Discount: https://www.stratagemmarketinsights.com/discount/8711

Get in Touch:

Mr. Shah
Stratagem Market Insights
Tel: +1-415-871-0703
Email: sales@stratagemmarketinsights.com
Visit Here: https://deep-research-report.blogspot.com/

About Us:

Stratagem Market Insights is a management consulting organization providing market intelligence and consulting services worldwide. We bring the expertise of consultants with an cumulative industry experience of more than 70 years. The firm has been providing quantified B2B research and currently offers services to over 350+ customers worldwide. Our reports cover various end-use industries such as Aerospace and Defense, Agriculture, Food and Beverages, Automotive, Chemicals and Materials, Consumer Goods and Retail, Electronics, Energy, Mining, and Utilities, Pharmaceuticals, Manufacturing and Construction, Services, and Healthcare, and ICT.

This release was published on openPR.